Clinical trials: Stage II Skin Cancer
Metastatic Breast Cancer
A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer
The purpose of this study is to compare the efficacy and tolerability of Faslodex (fulvestrant) with Arimidex (anastrozole) in postmenopausal women with hormone receptor positive advanced breast cancer.
- Trial name
- FIRST (NCT00274469)
- Testing
- fulvestrant, anastrozole
- Where
- 41 sites in United States, Brazil and 7 more
- Volunteers
- 205 people
- Sponsor
- AstraZeneca
Melanoma (Skin)
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00118274
- Testing
- incomplete Freund's adjuvant, melanoma helper peptide vaccine, multi-epitope melanoma peptide vaccine
- Where
- 3 sites in United States
- Volunteers
- 170 people
- Sponsor
- Craig L Slingluff, Jr
Melanoma
Trial of pIL-12/MK-3475 in Metastatic Melanoma
This is a multicenter, Phase II, open-label, 42-patient single-arm trial of intratumoral pIL-12 electroporation (EP) in combination with pembrolizumab in patients with melanoma. Patients will be evaluated in 2 parts.
- Trial name
- NCT02493361
- Testing
- Pembrolizumab, pIL-12
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of California, San Francisco
Melanoma
Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma
This is a single-arm, open label, Phase II study evaluating the safety and efficacy of neoadjuvant Nivolumab and HF10 in resectable stage IIIB, IIIC, and IVM1a melanoma.
- Trial name
- NCT03259425
- Testing
- Nivolumab, HF10
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Utah
Breast Cancer
Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)
The goal of this clinical research study is to learn if Ofev® (nintedanib, also called BIBF1120) can help to control IBC. The safety of this drug will also be studied. This is an investigational study.
- Trial name
- NCT02389764
- Testing
- BIBF 1120, Phone Call
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Metastatic Cancer
Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases
RATIONALE: Drugs used in chemotherapy, such as irinotecan and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00617539
- Testing
- irinotecan hydrochloride, temozolomide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
Breast Cancer
Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa
This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational drug, which is cisplatin in this trial, to learn how well it works in treating a specific cancer.
- Trial name
- NCT01670500
- Testing
- Cisplatin, Cyclophosphamide, Doxorubicin
- Where
- 15 sites in United States
- Volunteers
- 118 people
- Sponsor
- Beth Israel Deaconess Medical Center
Breast Cancer
Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00765765
- Testing
- hydroxychloroquine, ixabepilone
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Breast Cancer
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
This randomized phase III trial studies cyclophosphamide and doxorubicin hydrochloride compared with paclitaxel as adjuvant therapy in treating breast cancer in women with 0-3 positive axillary lymph nodes.
- Trial name
- NCT00041119
- Testing
- AC regimen, cyclophosphamide, doxorubicin hydrochloride
- Where
- 527 sites in United States, South Africa
- Volunteers
- 3,871 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer
This is a randomized, double-blind, placebo-controlled, multicenter, pre-operative Phase II study designed to estimate the efficacy of ipatasertib combined with paclitaxel chemotherapy versus placebo combined with paclitaxel…
- Trial name
- NCT02301988
- Testing
- Ipatasertib, Paclitaxel
- Where
- 42 sites in United States, Portugal and 1 more
- Volunteers
- 151 people
- Sponsor
- Genentech, Inc.
Breast Cancer
Cryoablation Therapy in Treating Patients With Invasive Ductal Breast Cancer
This phase II trial is studying how well cryoablation therapy works in treating patients with invasive ductal breast cancer. Cryoablation kills tumor cells by freezing them.
- Trial name
- NCT00723294
- Testing
- cryosurgery, therapeutic conventional surgery
- Where
- 16 sites in United States
- Volunteers
- 99 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity
This was a phase III, randomized, double blind, multicenter, 2-arm study evaluating the efficacy and safety of amcenestrant compared with tamoxifen in participants with hormone receptor-positive early breast cancer who…
- Trial name
- AMEERA-6 (NCT05128773)
- Testing
- Amcenestrant, Tamoxifen
- Where
- 2 sites in Chile, China
- Volunteers
- 3 people
- Sponsor
- Sanofi
Metastatic Breast Cancer
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
The purpose of this study is to find out what effect the combination of letrozole (brand name: Femara) and dasatinib (brand name: Sprycel) has on metastatic breast cancer compared to letrozole alone
- Trial name
- NCT00696072
- Testing
- Dasatinib, Letrozole
- Where
- 27 sites in United States
- Volunteers
- 120 people
- Sponsor
- Bristol-Myers Squibb
Malignant Melanoma
Lapatinib in Stage IV Melanoma With ERBB4 Mutations
Background: Studies of melanoma tumor samples have shown that tumor cells from approximately 20 percent of melanoma patients contain a specific mutation of a gene involved in making a protein called ERBB4, and that changes in…
- Trial name
- NCT01264081
- Testing
- Lapatinib
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
This was a randomized, double-blind, placebo-controlled study conducted in Chinese women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer, plus an open-label…
- Trial name
- NCT03671330
- Testing
- Ribociclib, NSAI: Letrozole or Anastrazole, Goserelin
- Where
- 24 sites in China
- Volunteers
- 327 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Trial name
- NCT00856492
- Testing
- bevacizumab, pegfilgrastim, cyclophosphamide
- Where
- 366 sites in United States, Puerto Rico
- Volunteers
- 215 people
- Sponsor
- SWOG Cancer Research Network
Metastatic Breast Cancer
Her2-BATS and Pembrolizumab in Metastatic Breast Cancer
This proposal uses HER2Bi armed activated T-cells (HER2 BATs) to target breast cancer in combination with pembrolizumab (PBZ) in women with metastatic breast cancer (MBC).
- Trial name
- Breast-47 (NCT03272334)
- Testing
- HER2 BATs with Pembrolizumab
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Virginia
Breast Carcinoma, Endometrial Clear Cell Adenocarcinoma
Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer
This phase II trial studies how well metformin hydrochloride works together with doxycycline in treating patients with localized breast or uterine cancer.
- Conditions
- Breast Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Uterine Corpus Cancer
- Trial name
- NCT02874430
- Testing
- Metformin Hydrochloride, Doxycycline
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Melanoma
Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting
The main goal of this study is to evaluate the antitumor activity of relatlimab and nivolumab in combination in subjects with unresectable or metastatic melanoma who have not received prior treatment with immunotherapy.
- Trial name
- NCT03743766
- Testing
- Relatlimab, Nivolumab, Relatlimab + Nivolumab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- John Kirkwood
Breast Cancer
PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT00499681
- Testing
- lapatinib ditosylate, letrozole
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.